Novo Nordisk A/S $NVO Shares Sold by Private Wealth Partners LLC

Private Wealth Partners LLC lessened its holdings in Novo Nordisk A/S (NYSE:NVO) by 59.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 21,638 shares of the company’s stock after selling 31,955 shares during the period. Private Wealth Partners LLC’s holdings in Novo Nordisk A/S were worth $1,201,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the business. True Wealth Design LLC increased its position in Novo Nordisk A/S by 209.8% during the third quarter. True Wealth Design LLC now owns 443 shares of the company’s stock worth $25,000 after buying an additional 300 shares in the last quarter. NewSquare Capital LLC boosted its stake in shares of Novo Nordisk A/S by 174.1% during the second quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock valued at $31,000 after acquiring an additional 282 shares during the last quarter. Mid American Wealth Advisory Group Inc. acquired a new stake in shares of Novo Nordisk A/S during the second quarter valued at $37,000. Copeland Capital Management LLC increased its position in Novo Nordisk A/S by 47.3% during the 2nd quarter. Copeland Capital Management LLC now owns 579 shares of the company’s stock worth $40,000 after purchasing an additional 186 shares in the last quarter. Finally, Steigerwald Gordon & Koch Inc. acquired a new position in Novo Nordisk A/S in the 3rd quarter valued at about $39,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently commented on NVO shares. Morgan Stanley reiterated an “underweight” rating and set a $42.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, December 3rd. Argus reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, December 8th. Citigroup started coverage on Novo Nordisk A/S in a report on Tuesday. They issued a “neutral” rating for the company. Jefferies Financial Group started coverage on Novo Nordisk A/S in a research note on Monday, October 27th. They set an “underperform” rating on the stock. Finally, BMO Capital Markets set a $57.00 price objective on Novo Nordisk A/S in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have given a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of “Hold” and an average target price of $57.79.

Novo Nordisk A/S Price Performance

NVO opened at $59.40 on Friday. Novo Nordisk A/S has a 52-week low of $43.08 and a 52-week high of $93.80. The company has a 50 day moving average of $53.44 and a two-hundred day moving average of $54.50. The company has a market cap of $265.23 billion, a P/E ratio of 17.27 and a beta of 0.66. The company has a quick ratio of 0.57, a current ratio of 0.78 and a debt-to-equity ratio of 0.52.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, beating the consensus estimate of $0.77 by $0.25. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. The business had revenue of $11.79 billion for the quarter, compared to analyst estimates of $11.98 billion. On average, analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Very strong launch demand for Wegovy pill: IQVIA data show the pill tracked over 26,000 U.S. prescriptions in its second full week, signaling rapid uptake that supports revenue upside and market share gains in the obesity market. Novo’s Wegovy pill tracks over 26,000 prescriptions
• Positive Sentiment: Early sales momentum reinforced by reporting of ~18,000 U.S. prescriptions in week one and commentary that demand is “strong out of the gate,” which supports upside to near‑term sales and investor sentiment. Demand for Novo Nordisk’s Weight Loss Pill Is Strong Out of the Gate. Is the Stock Due for a Big Rally?
• Neutral Sentiment: Analyst view is mixed — one upgrade highlights first‑mover advantage, strong cash and aggressive U.S. marketing but also flags high valuation and potential for near‑term profit‑taking, leading to a cautious “Hold” posture. Novo Nordisk: Momentum Meets Headwinds Before Earnings (Upgrade)
• Neutral Sentiment: Public profile of Novo’s weight‑loss boom is increasing (e.g., a new Danish theatre piece), which is PR‑positive but not directly material to near‑term financials. New play in Denmark charts Novo Nordisk’s weight loss boom
• Negative Sentiment: Leadership change in China: Senior VP and head of China Christine Zhou will step down at end‑of‑March — a potential disruption given China’s importance for growth and ongoing market expansion. Novo Nordisk’s China President Zhou to step down in March
• Negative Sentiment: Near‑term headwinds flagged: analysts warn of slowing Wegovy/Ozempic momentum, pricing pressure and stronger competition that could limit upside to sales growth and margins into the Q4 earnings release. Novo Nordisk Before Q4 Earnings: How Should Investors Play the Stock?

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.